A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)

Summary

The primary purpose of this study is to evaluate the safety of SRP-6004 administered by intravenous (IV) infusion in ambulatory participants with LGMD2B/R2 (DYSF related).

Timeline

Start

2023-05-22

Primary completion

2025-06-13

Completion

2025-06-13

Outcome

Outcome not reported

Stopped (Business): “Study is being terminated due to a business decision.”

Drugs

Indications